These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 22846432)

  • 1. Differential response to intracellular stress in the skin from osteogenesis imperfecta Brtl mice with lethal and non lethal phenotype: a proteomic approach.
    Bianchi L; Gagliardi A; Gioia R; Besio R; Tani C; Landi C; Cipriano M; Gimigliano A; Rossi A; Marini JC; Forlino A; Bini L
    J Proteomics; 2012 Aug; 75(15):4717-33. PubMed ID: 22846432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered cytoskeletal organization characterized lethal but not surviving Brtl+/- mice: insight on phenotypic variability in osteogenesis imperfecta.
    Bianchi L; Gagliardi A; Maruelli S; Besio R; Landi C; Gioia R; Kozloff KM; Khoury BM; Coucke PJ; Symoens S; Marini JC; Rossi A; Bini L; Forlino A
    Hum Mol Genet; 2015 Nov; 24(21):6118-33. PubMed ID: 26264579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential expression of both extracellular and intracellular proteins is involved in the lethal or nonlethal phenotypic variation of BrtlIV, a murine model for osteogenesis imperfecta.
    Forlino A; Tani C; Rossi A; Lupi A; Campari E; Gualeni B; Bianchi L; Armini A; Cetta G; Bini L; Marini JC
    Proteomics; 2007 Jun; 7(11):1877-91. PubMed ID: 17520686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytoskeleton and nuclear lamina affection in recessive osteogenesis imperfecta: A functional proteomics perspective.
    Gagliardi A; Besio R; Carnemolla C; Landi C; Armini A; Aglan M; Otaify G; Temtamy SA; Forlino A; Bini L; Bianchi L
    J Proteomics; 2017 Sep; 167():46-59. PubMed ID: 28802583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracellular and Extracellular Markers of Lethality in Osteogenesis Imperfecta: A Quantitative Proteomic Approach.
    Bini L; Schvartz D; Carnemolla C; Besio R; Garibaldi N; Sanchez JC; Forlino A; Bianchi L
    Int J Mol Sci; 2021 Jan; 22(1):. PubMed ID: 33406681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective retention and degradation of molecules with a single mutant alpha1(I) chain in the Brtl IV mouse model of OI.
    Forlino A; Kuznetsova NV; Marini JC; Leikin S
    Matrix Biol; 2007 Oct; 26(8):604-14. PubMed ID: 17662583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure, stability and interactions of type I collagen with GLY349-CYS substitution in alpha 1(I) chain in a murine Osteogenesis Imperfecta model.
    Kuznetsova NV; Forlino A; Cabral WA; Marini JC; Leikin S
    Matrix Biol; 2004 May; 23(2):101-12. PubMed ID: 15246109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of the Cre/lox recombination system to develop a non-lethal knock-in murine model for osteogenesis imperfecta with an alpha1(I) G349C substitution. Variability in phenotype in BrtlIV mice.
    Forlino A; Porter FD; Lee EJ; Westphal H; Marini JC
    J Biol Chem; 1999 Dec; 274(53):37923-31. PubMed ID: 10608859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotype-phenotype correlation study in 364 osteogenesis imperfecta Italian patients.
    Maioli M; Gnoli M; Boarini M; Tremosini M; Zambrano A; Pedrini E; Mordenti M; Corsini S; D'Eufemia P; Versacci P; Celli M; Sangiorgi L
    Eur J Hum Genet; 2019 Jul; 27(7):1090-1100. PubMed ID: 30886339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In utero transplantation of adult bone marrow decreases perinatal lethality and rescues the bone phenotype in the knockin murine model for classical, dominant osteogenesis imperfecta.
    Panaroni C; Gioia R; Lupi A; Besio R; Goldstein SA; Kreider J; Leikin S; Vera JC; Mertz EL; Perilli E; Baruffaldi F; Villa I; Farina A; Casasco M; Cetta G; Rossi A; Frattini A; Marini JC; Vezzoni P; Forlino A
    Blood; 2009 Jul; 114(2):459-68. PubMed ID: 19414862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased susceptibility to microdamage in Brtl/+ mouse model for osteogenesis imperfecta.
    Davis MS; Kovacic BL; Marini JC; Shih AJ; Kozloff KM
    Bone; 2012 Mar; 50(3):784-91. PubMed ID: 22207275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allele-specific Col1a1 silencing reduces mutant collagen in fibroblasts from Brtl mouse, a model for classical osteogenesis imperfecta.
    Rousseau J; Gioia R; Layrolle P; Lieubeau B; Heymann D; Rossi A; Marini JC; Trichet V; Forlino A
    Eur J Hum Genet; 2014 May; 22(5):667-74. PubMed ID: 24022296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impaired osteoblastogenesis in a murine model of dominant osteogenesis imperfecta: a new target for osteogenesis imperfecta pharmacological therapy.
    Gioia R; Panaroni C; Besio R; Palladini G; Merlini G; Giansanti V; Scovassi IA; Villani S; Villa I; Villa A; Vezzoni P; Tenni R; Rossi A; Marini JC; Forlino A
    Stem Cells; 2012 Jul; 30(7):1465-76. PubMed ID: 22511244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell differentiation and matrix organization are differentially affected during bone formation in osteogenesis imperfecta zebrafish models with different genetic defects impacting collagen type I structure.
    Daponte V; Tonelli F; Masiero C; Syx D; Exbrayat-Héritier C; Biggiogera M; Willaert A; Rossi A; Coucke PJ; Ruggiero F; Forlino A
    Matrix Biol; 2023 Aug; 121():105-126. PubMed ID: 37336269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brittle IV mouse model for osteogenesis imperfecta IV demonstrates postpubertal adaptations to improve whole bone strength.
    Kozloff KM; Carden A; Bergwitz C; Forlino A; Uveges TE; Morris MD; Marini JC; Goldstein SA
    J Bone Miner Res; 2004 Apr; 19(4):614-22. PubMed ID: 15005849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoscale morphology of Type I collagen is altered in the Brtl mouse model of Osteogenesis Imperfecta.
    Wallace JM; Orr BG; Marini JC; Holl MM
    J Struct Biol; 2011 Jan; 173(1):146-52. PubMed ID: 20696252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Local amino acid sequence patterns dominate the heterogeneous phenotype for the collagen connective tissue disease Osteogenesis Imperfecta resulting from Gly mutations.
    Xiao J; Yang Z; Sun X; Addabbo R; Baum J
    J Struct Biol; 2015 Oct; 192(1):127-37. PubMed ID: 25980613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The chaperone activity of 4PBA ameliorates the skeletal phenotype of Chihuahua, a zebrafish model for dominant osteogenesis imperfecta.
    Gioia R; Tonelli F; Ceppi I; Biggiogera M; Leikin S; Fisher S; Tenedini E; Yorgan TA; Schinke T; Tian K; Schwartz JM; Forte F; Wagener R; Villani S; Rossi A; Forlino A
    Hum Mol Genet; 2017 Aug; 26(15):2897-2911. PubMed ID: 28475764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapidly growing Brtl/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment.
    Sinder BP; Salemi JD; Ominsky MS; Caird MS; Marini JC; Kozloff KM
    Bone; 2015 Feb; 71():115-23. PubMed ID: 25445450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation and polymorphism spectrum in osteogenesis imperfecta type II: implications for genotype-phenotype relationships.
    Bodian DL; Chan TF; Poon A; Schwarze U; Yang K; Byers PH; Kwok PY; Klein TE
    Hum Mol Genet; 2009 Feb; 18(3):463-71. PubMed ID: 18996919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.